Dicerna, Roche ink $200M development, commercialization deal for chronic hep B drugs
The partnership will primarily focus on the drug DCR-HBVS, an RNA-interference drug that Dicerna is developing for HBV. The deal includes potential milestones of up to $1.47 billion.